32 results about "Hepatic lipase" patented technology

The present invention provides: a prophylactic or therapeutic agent for hepatic diseases, which comprises an AIM, a partial peptide of the AIM, or a nucleic acid comprising a nucleotide sequence encoding the AIM or the partial peptide; a method for screening for a prophylactic or therapeutic agent for hepatic diseases using an animal that is produced by feeding a high-fat diet to a non-human mammal with insufficient expression of an AIM; and others.

The disclosure provides oral compositions and methods of using such compositions in treating subjects infected with one or more hepatic disorders. The compositions include lysates or cell wall extracts of one or more gram positive bacteria, exhibit particular activity against hepatitis C virus (HCV), and may be useful in treating those infected with HCV as well as other hepatic diseases or disorders. Also described are methods of treating a hepatic disease or disorder by administering a therapeutically effective amount of at least one therapeutically active agent capable of upregulating or downregulating the Complement system pathway, wherein the therapeutically active agent enhances the formation of one or more convertase enzymes.

The invention provides application of yellow thorn fruits or extracts of the fruits to preparing medicines or health care products or food for treating dyslipidemia. The research shows that the yellow thorn fruits have the effect of treating the dyslipidemia, and cholesterol (TC), triglyceride (TG), low-density lipoprotein (LDL) and rising high-density lipoprotein (HDL) can be reduced; the enzymatic activity relevant to lipid metabolism can be improved, that is, the activity of the lipoprotein lipase and hepatic lipase can be improved; meanwhile, the activity of glutamic oxalacetic transaminase and glutamic-pyruvic transaminase can be reduced, no hurt to the liver tissue exists, and the fruits can be used as the good-safety medicines or the health care products or the food for treating the dyslipidemia.

The present invention relates to a kind of 2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside for reducing blood lipid, which is characterized in that it has the function of inhibiting the increase of serum total cholesterol, reducing serum low The functions such as density lipoprotein cholesterol and improving the activity of liver lipase can be made into medicine with this active monomer.

The present invention belongs to the field of medicine technology, and is especially a kind of medicine composition and its preparation process. The medicine composition is prepared with kurarinone 4-400 weight portions, glutathione 3-300 weight portions, and tiopronin 1-100 weight portions. The medicine composition may be prepared into different pharmaceutically acceptable forms, preferably injection and oral preparation. It has the pharmacological activities of antagonizing virus, improving liver cell function, antagonizing liver fibrosis, regulating immunity, diminishing inflammation, etc.and may be used in treating various hepatic diseases, viral hepatosis, medicinal hepatosis, alcoholic hepatosis, etc.

The invention provides an application of health care drinking liquid containing deep seawater in the preparation of medicaments or health care products for preventing or treating hyperlipoidemia. The health care drinking liquid comprises A liquid and B liquid, wherein the A liquid is of fresh water, the B liquid is of high-concentration concentrated liquid which is obtained by performing decompression concentration on a concentrated water part which is separated from the deep sweater via a reverse osmosis device, and the hardness range is 200-1000ppm. The health care drinking liquid is given to a rat with the hyperlipoidemia, which is subjected to modeling by a high-fat emulsion, in a free drinking way, after the medicament is administrated for 28 days, the blood lipid level of the rat with the hyperlipoidemia can be significantly reduced, lipid peroxidation can be inhibited, the activity of lipoprotein metabolic enzymes, namely LCAT (lecithin-cholesterol acetyltransferase), LPL (lipoprotein lipase) and HL (hepatic lipase), can be significantly improved, and the state of lipid metabolism disorder in the rat with the hyperlipoidemia, as well as concurrent fatty liver and diabetes thereof, can be further improved. The health care drinking liquid is derived from the deep seawater, has the advantages of abundant resources, easiness in industrialization and the like, and further has broad market and application prospects in the aspect of preventing and treating the hyperlipoidemia.